{"id":"W4416841363","doi":"10.1007/s40268-025-00530-9","title":"Safety, Tolerability and Pharmacokinetics of a High-Dose, Rapid-Infusion Monoclonal Antibody: Phase I Results for Intravenous Sotrovimab 3000 mg","year":2025,"lang":"en","type":"article","venue":"Drugs in R&D","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline Biologicals; Vir Biotechnology","keywords":"Pharmacokinetics; Tolerability; Monoclonal antibody; Phase (matter); Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007544231,0.0002200433,0.0006374184,0.0002938911,0.0001023929,0.00001520357,0.0001588128,0.0001265091,0.00006639375],"category_scores_gemma":[0.000289416,0.0001870473,0.0001212834,0.0003819122,0.000281386,0.00005096542,0.0001796745,0.0003265739,0.000003730074],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008142061,"about_ca_system_score_gemma":0.000307863,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005401645,"about_ca_topic_score_gemma":0.00001700588,"domain_scores_codex":[0.9979169,0.00008960922,0.0007739641,0.0004588717,0.0003413629,0.0004192773],"domain_scores_gemma":[0.9985752,0.0006469758,0.0001148166,0.0002983951,0.0002188955,0.0001456898],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.09424089,0.005612536,0.01008116,0.003627849,0.0004084345,0.0001047911,0.00250915,0.0001039062,0.1737114,0.00628775,0.00908204,0.6942301],"study_design_scores_gemma":[0.1610842,0.008746477,0.2379251,0.002525267,0.0006503104,0.0001099497,0.001091353,0.05620447,0.205121,0.01453445,0.3106502,0.001357178],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862097,0.001083097,0.0004067753,0.005931778,0.0002133563,0.00111768,0.0007267203,0.00002754516,0.004283354],"genre_scores_gemma":[0.9928413,0.00178317,0.002945377,0.0003803659,0.0001391962,0.00003442512,0.0003749921,0.00001614228,0.001485039],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6928729,"threshold_uncertainty_score":0.7627566,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01954396181163665,"score_gpt":0.3693013937195685,"score_spread":0.3497574319079318,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}